Royalty Report: Drugs, Therapeutic, Disease – Collection: 213673

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Biotechnology
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 213673

License Grant
The Parties agree to amend the terms of the Agreement pursuant to which Licensor appointed Licensee as their exclusive channel collaborator for developing and commercializing certain products in an exclusive field as defined by the Agreement.
License Property
The collaboration agreement is for the development and commercialization of lantibiotics, a novel class of broad spectrum antibiotics, as active pharmaceutical ingredients (API) for the treatment of infectious diseases in humans and companion animals.

Lantibiotics, a class of peptide antibiotics that are naturally produced in Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine.  In connection with the research, development, use, importing, manufacture, sale, and offer for sale of drug products involving the direct administration to humans or companies of lantibiotics for the purpose of prevention or treatment of infectious disease.

Field of Use
This agreement pertains to the drug industry.  The Licensee will develop and produce lantibiotics, a class of peptide antibiotics that are naturally produced in Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine.

IPSCIO Record ID: 28615

License Grant
The Channel Agreement grants the Licensee an exclusive worldwide License to use patents and other intellectual property of the Licensor in connection with the research, development, use, importing, manufacture, sale, and offer for sale of drug products involving the direct administration to humans or companies of lantibiotics for the purpose of prevention or treatment of infectious disease.
License Property
Such License is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of Licensee Products, and otherwise is non-exclusive. Subject to limited exceptions, the Licensee may not subLicense the rights described without written consent.

During the first 18 months of the Agreement, neither the Licensor or Licensee may terminate the Channel Agreement other than in the event of a material breach. Following the first 18 months of the Agreement, the Licensor may also terminate the Channel Agreement if the Company fails to use diligent efforts to develop and commercialize Products or if the Licensee elects not to pursue the development of a Lantibiotics Program identified by the Licensor that is a Superior Therapy as defined in the Channel Agreement. Following the first 18 months of the Agreement, the Licensee may voluntarily terminate the Channel Agreement at any time upon 90 days written notice.
l
Upon termination of the Channel Agreement, the Licensee may continue to develop and commercialize any Product that, at the time of termination

is being commercialized by the Licensee;
has received regulatory approval;
is a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or
is the subject of at least an ongoing Phase I, Phase A, Phase II or Phase III clinical trial, or an ongoing Phase I clinical trial in the Field.

Field of Use
The Licensee will develop and produce lantibiotics, a class of peptide antibiotics that are naturally produced in Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine.

IPSCIO Record ID: 209550

License Grant
Licensor grants the sole and exclusive, perpetual, transferable, and world-wide rights and licenses, with the right to sublicense, to use proprietary information, technical information and patented technology in developing, manufacturing, having manufactured, using, selling, marketing, or distributing the Licensed Products.

Licensor grants  the non-exclusive, perpetual, transferable rights and licenses, with the right to sublicense, to use the Proprietary Information, Technical Information and Patented Technology for manufacture of Lysostaphin Preparations for use by Licensee in research, in the Licensed Products, and for sale to Licensor or its designee.

License Property
The licensed products are Drugs for Human Use which means Lysostaphin preparations for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases in humans.  

The proprietary information is Lysostaphin Production for E. coli production strain; Bacillus Sphericus production strain; and Manufacturing processes.

Lysostaphin is a Staphylococcus simulans metalloendopeptidase. It can function as an antimicrobial against Staphylococcus aureus.

The Technical information is all information other than proprietary information.

U.S. Patent No. 4,931,390 – Expression Of The Cloned Lysostaphin Gene
U.S. Patent No. 4,980,163 – Novel Bacteriocin Compositions For Use As Enhanced Broad Range Bactericides And Methods Of Preventing And Treating Microbial Infection
U.S. Patent No. 5,760,026 – Method For Treating Mastitis And Other Staphylococcal Infections
U.S. Patent No. 5,858,962 – Compositions For Treating Mastitis And Other Staphylococcal Infections
U.S. Patent No. 6,028,051 – Method For The Treatment Of Staphylococcal Disease
Serial No. 09/120,030 – A Method For The Treatment Of Staphylococcal Disease
Serial No. 09/263,776 – Compositions And Methods For Treatment of Stphylococcal Infection While Suppressing Formation of Antibiotic-Resistant Strains

Field of Use
The products are used for Treating Mastitis And Other Staphylococcal Infections.

Mastitis is inflammation of the breast or udder, usually associated with breastfeeding.
Staphylococcus is a genus of Gram-positive bacteria that can cause a wide variety of infections in humans and other animals through infection or the production of toxins. Staphylococcal toxins are a common cause of food poisoning, as they can be produced in improperly-stored food.

IPSCIO Record ID: 26258

License Grant
The agreement grants access to new analogs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics with improved pharmacological properties and structural features.
License Property
These novel antibiotics may be useful to treat or prevent colonization and/or infections by one or more types of bacteria. The structural changes available to us from this license agreement may improve the bioactivity of MU1140. Under the terms of this license agreement, we filed two patent applications with the US Patent Office to secure the intellectual property related to these new lantibiotic analogs.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.